Does Rallies show Form 4 insider transactions for IRWD?

Yes. Rallies tracks IRWD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IRWD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IRWD. It does not provide personalized investment advice.

IRWD (Ironwood Pharmaceuticals, Inc. - Class A) Stock Analysis - Insider Trades

Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is a publicly traded Healthcare sector company. As of May 21, 2026, IRWD trades at $3.85 with a market cap of $576.15M and a P/E ratio of 5.98. IRWD moved +6.81% today. Year to date, IRWD is -14.60%; over the trailing twelve months it is +500.86%. Its 52-week range spans $0.53 to $5.78. Analyst consensus is buy with an average price target of $7.50. Rallies surfaces IRWD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IRWD stock inside the company?

Recent IRWD insider activity includes DENNER ALEXANDER J sold 6.72M, DENNER ALEXANDER J sold 5.80K, John Minardo sold 19.05K, Shetzline Michael bought 17.01K, and Gaskins Tammi L sold 11.24K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IRWD Key Metrics

Key financial metrics for IRWD
Metric	Value
Price	$3.85
Market Cap	$576.15M
P/E Ratio	5.98
EPS	$0.64
Dividend Yield	0.00%
52-Week High	$5.78
52-Week Low	$0.53
Volume	5.04K
Avg Volume	0
Revenue (TTM)	$361.51M
Net Income	$102.18M
Gross Margin	0.00%

Recent IRWD Insider Trades

DENNER ALEXANDER J sold 6.72M (~$20.51M) on Mar 17, 2026.
DENNER ALEXANDER J sold 5.80K (~$19.20K) on Mar 17, 2026.
John Minardo sold 19.05K (~$69.73K) on Feb 24, 2026.
Shetzline Michael bought 17.01K (~$62.26K) on Feb 24, 2026.
Gaskins Tammi L sold 11.24K (~$41.13K) on Feb 24, 2026.

Latest IRWD News

Ironwood Delivers $0.24 EPS in Q1, Tops Estimates After Prior-Year Loss — May 7, 2026
Ironwood Q4 Misses Estimates with 47.3% Revenue Drop and CNP-104 Setback — Feb 26, 2026
Ironwood Q4 EPS Loss of $0.01 Reverses Prior-Year Profit — Feb 25, 2026
Ironwood Pharmaceuticals Shares Up 129% Hold Top Analyst Ranking, Q4 Results Due Feb. 26 — Feb 13, 2026
Ironwood Lifts 2026 Revenue Forecast, Shares Jump 27% on LINZESS Demand — Jan 5, 2026

IRWD Analyst Consensus

3 analysts cover IRWD: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.50.

Common questions about IRWD

Who is trading IRWD stock inside the company?: Recent IRWD insider activity includes DENNER ALEXANDER J sold 6.72M, DENNER ALEXANDER J sold 5.80K, John Minardo sold 19.05K, Shetzline Michael bought 17.01K, and Gaskins Tammi L sold 11.24K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IRWD?: Yes. Rallies tracks IRWD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IRWD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IRWD. It does not provide personalized investment advice.